COMP <GO>
ROIV vs VTRS // 10Y YIELD & FRED MACRO BETA
Roivant Sciences Ltd. (NASDAQ) VS. Viatris Inc. (NASDAQ) • 15-METRIC TALLY: ROIV 3
— VTRS 8
▲ 10Y YIELD & FRED MACRO BETA LEADER: VTRS
LAST: $36.91 (-1.63%) • MKT CAP: $26.66B
macro-sensitivity
1.00
LAST: $19.04 (-0.86%) • MKT CAP: $21.86B
macro-sensitivity
1.15
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ROIV VS. VTRS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ROIV | VTRS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 35.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -14.00% | -8.10% | -5.90 | VTRS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.80% | 8.78% | -11.58 | VTRS | /fcf-yield <GO> |
| Operating Margin | -60.00% | -18.70% | -41.30 | VTRS | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -14.60% | -45.40 | VTRS | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | -3.00% | -62.00 | VTRS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 0.81 | +25.19 | ROIV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 6/9 | -3.00 | VTRS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.3 | 62.5 | -9.20 | VTRS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.00 | 1.15 | -0.15 | VTRS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 33.0x | -5.00 | ROIV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $26.66B | $21.86B | $4.80B | ROIV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ROIV REV | VTRS REV | ROIV GROSS % | VTRS GROSS % | ROIV FCF | VTRS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.3M | $14.25B | — | 35.2% | -$758.6M | $1.94B |
| FY 2024 | $29.1M | $14.69B | — | 38.3% | -$844.0M | $1.98B |
| FY 2023 | $32.7M | $15.39B | — | — | -$766.7M | $2.21B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ROIV // BETA 1.00
VTRS // BETA 1.15